Value Sense
BLTE
Belite Bio, Inc (BLTE)
Last Price$68.62.5%
Market Cap$2,075.9M
LTM Net Debt to Free Cash Flow
N/A
5Y avg
574.0x
Biotechnology industry median
1.0x
Stock quality & Intrinsic value
5/10
(0.8%) overvalued
BLTE
is (76.6%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Belite Bio, Inc Net Debt to Free Cash Flow

Annual
Quarterly
LTM
Industry median
Company stand-alone
BLTE
Healthcare
Crunching data... Almost there!
Dec'20Dec'21Dec'22Dec'23
Net Debt to Free Cash Flow
5.7x
2.3x
3.5x
2.9x
BLTE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BLTE and see if it's the right time to invest.
Dive in

Belite Bio, Inc (BLTE) Net Debt to Free Cash Flow comparison analysis

General

LTM Net Debt to Free Cash Flow

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Belite Bio, Inc logo
Belite Bio, IncBLTE
N/A
N/A
91.9%
N/A
Median Peer Set
1.8x
14.8%
(19.3%)
7.5%
BioNTech SE logo
BioNTech SEBNTX
71.9x
(77.4%)
(89.7%)
24.4%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
32.8x
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
5.5x
11.7%
N/A
(4.9%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
2.9x
N/A
(68.7%)
N/A
Royalty Pharma plc logo
Royalty Pharma plcRPRX
2.1x
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
1.5x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
(1.1x)
18.0%
139.3%
15.0%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
(2.7x)
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
(4.4x)
8.3%
10.4%
31.1%
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)

BLTE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.20.4
Gross Profit
% margin
(0.0)
0.0%
(0.0)
0.0%
(0.2)
0.0%
(0.4)
0.0%
Operating Expenses5.79.812.831.7
Research & Development Expenses (R&D)3.77.48.924.8
Selling, General & Administrative Expenses (SG&A)2.12.44.06.8
Operating Income
% margin
(5.7)
0.0%
(9.8)
0.0%
(12.8)
0.0%
(31.7)
0.0%
Interest Income0.00.00.00.1
Interest Expense0.00.00.00.0
Pre-tax Income(5.8)(9.7)(12.6)(31.6)
Income Tax
% effective tax rate
0.0
(0.0%)
0.1
(1.3%)
(0.2)
1.4%
0.0
(0.0%)
Net Income
% margin
(5.8)
0.0%
(9.8)
0.0%
(12.5)
0.0%
(31.6)
0.0%
EPS(0.24)(0.41)(0.62)(1.19)
Diluted EPS(0.24)(0.41)(0.62)(1.19)
EBITDA
% margin
(5.7)
0.0%
(9.6)
0.0%
(12.4)
0.0%
(31.5)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Belite Bio, Inc's Net Debt to Free Cash Flow?

As of today, Microsoft Corp's last 12-month Net Debt to Free Cash Flow is N/A, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Net Debt to Free Cash Flow for Belite Bio, Inc have been 364.4x over the past three years, and 545.3x over the past five years.

2) Is Belite Bio, Inc's Net Debt to Free Cash Flow Good?

As of today, Belite Bio, Inc's Net Debt to Free Cash Flow is N/A, which is N/A than industry median of 1.0x. It indicates that Belite Bio, Inc's Net Debt to Free Cash Flow is undefined.

3) How does Belite Bio, Inc's Net Debt to Free Cash Flow compare to its peers?

As of today, Belite Bio, Inc's Net Debt to Free Cash Flow is N/A, which is N/A than peer median of 1.8x. The list of peers includes BNTX, ALNY, VRTX, SMMT, RPRX, BGNE, BMRN, UTHR, REGN, ARGX.